chondroitin-sulfates has been researched along with phytochlorin* in 3 studies
3 other study(ies) available for chondroitin-sulfates and phytochlorin
Article | Year |
---|---|
Chondroitin sulfate-based nanoparticles for enhanced chemo-photodynamic therapy overcoming multidrug resistance and lung metastasis of breast cancer.
As a major therapeutic approach for cancer treatment, the effectiveness of chemotherapy is challenged by multidrug resistance (MDR). Herein, we fabricated novel redox-responsive, chondroitin sulfate-based nanoparticles that could simultaneously deliver quercetin (chemosensitizer), chlorin e6 (photosensitizer) and paclitaxel (chemotherapeutic agent) to exert enhanced chemo-photodynamic therapy for overcoming MDR and lung metastasis of breast cancer. In vitro cell study showed that nanoparticles down-regulated the expression of P-glycolprotein (P-gp) on MCF-7/ADR cells and thereby improved the anticancer efficacy of PTX against MCF-7/ADR cells. Moreover, NIR laser irradiation could induce nanoparticles to generate cellular reactive oxygen species (ROS), leading to mitochondrial membrane potential loss, and meanwhile facilitating lysosomal escape of drugs. Importantly, the novel nanoplatform exhibited effective in vivo MDR inhibition and anti-metastasis efficacy through enhanced chemo-photodynamic therapy. Thus, the study suggested that the multifunctional nanoplatform had good application prospect for effective breast cancer therapy. Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Proliferation; Chlorophyllides; Chondroitin Sulfates; Combined Modality Therapy; Doxorubicin; Drug Carriers; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Infrared Rays; Lasers; Lung Neoplasms; MCF-7 Cells; Nanoparticles; Paclitaxel; Photosensitizing Agents; Porphyrins; Quercetin; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2021 |
Crosslinked self-assembled nanoparticles for chemo-sonodynamic combination therapy favoring antitumor, antimetastasis management and immune responses.
Sonodynamic therapy (SDT) has been proposed as a new modality for cancer management through low-intensity ultrasound induced activation of sonosensitizers. Here, we designed a novel redox/enzyme/ultrasound responsive chondroitin sulfate-chlorin e6-lipoic acid nanoplatform loading docetaxel, combining SDT and chemotherapy, for antiproliferation and antimetastasis of melanoma. The reversibly crosslinked and self-assembled nanoparticles possessed monodispersive size distribution, stability in physical conditions, while showing increased uptake with rapid drug release in simulated tumor microenvironment (reductive potentials and degradative hyaluronidase-1). With synthesized ultrasound sensitive polymer backbones, SDT induced the generation of cellular reactive oxygen species and mitochondrial damage, exerting the apoptotic effect through the release of cytochrome C, the expression of cleaved caspase-9 followed by the functional cleaved caspase-3. Chemo-sonodynamic therapy not only inhibited tumor growth and metastasis with reduced metastatic protein expression, but also caused immune response via the release of tumor-associated antigens. It was initially demonstrated that SDT could induce the tumor cell death, therefore having potentials to recruit cytotoxic lymphocytes into tumor sites. Notably, the nanoplatforms exhibited good in vivo stability and blood compatibility, indicating the safety and efficiency in drug delivery. Our work thus presents a convenient approach to fabricate intelligent multifunctional nanoparticles and paves a path for effective cancer therapies. Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chlorophyllides; Chondroitin Sulfates; Combined Modality Therapy; Docetaxel; Melanoma; Mice, Inbred C57BL; Nanoparticles; Porphyrins; Thioctic Acid; Ultrasonic Therapy | 2018 |
Self-assembled chlorin e6 conjugated chondroitin sulfate nanodrug for photodynamic therapy.
Acetylated-chondroitin sulfate/chlorin e6 conjugates (Ac-CS/Ce6 1, 2, 3) were synthesized via the formation of an ester linkage between CS and Ce6 and evaluated as nanoscale drugs for photodynamic therapy. Ac-CS/Ce6 2 and 3 with higher Ce6 contents of 11.7 and 17.6%, respectively, had average diameters of <150 nm and were very stable in phosphate-buffered saline (PBS) for 1 month. The critical self-quenching concentration (CQC) of Ac-CS/Ce6 decreased as the conjugated-amount of Ce6 increased. All samples displayed autophotoquenching properties in aqueous solution, whereas their fluorescence intensity strongly correlated with the amount of Ce6 in the organic solvent dimethyl sulfoxide (DMSO). Compared with free Ce6, Ac-CS/Ce6 nanodrug photoactivity was maintained in terms of fluorescence properties and singlet oxygen ((1)O(2)) generation. In a HeLa cell culture system, we observed rapid cellular uptake of the Ac-CS/Ce6 nanodrug without any other ligands using confocal imaging and fluorescence-activated cell sorting (FACS) analysis. Upon light irradiation following cellular uptake, phototoxicity was detected via 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. The self-quenching effect and fluorescence recovery of Ac-CS/Ce6 were also determined both in vitro and in vivo. Taken together, our results indicate that Ac-CS/Ce6 has potential as an effective photodynamic therapy (PDT) prodrug for clinical application. Topics: Animals; Chlorophyllides; Chondroitin Sulfates; Flow Cytometry; HeLa Cells; Humans; Mice; Microscopy, Confocal; Microscopy, Fluorescence; Nanotechnology; Photochemotherapy; Porphyrins | 2011 |